CD274 and glioma: A meta-analysis of three randomized controlled trials with 1,645 glioma patients (822 in the anti-PD-1/PD-L1 group and 823 in the control group) indicated that anti-PD-1/PD-L1 treatment was linked to a reduced OS compared to RT and TMZ, with or without placebo or BVZ (HR 1.15, 95% CI 1.03–1.29; moderate-quality evidence, Class IV) (Figure 3) [20].